Company intends to 31,500 million price issue of shares and payment of cash to buy a 70% stake in Thai Biological its total holdings to Xinde Fang, Xinli Kun and other eight individuals. Equity and cash to purchase issued shares held by a wholly-owned subsidiary of Hong Kong-East, after the completion of the acquisition, biological and Thailand will become a subsidiary of Hong Kong-East. At the same time, 83.5% stake in the company to 6,513 million copper prices XINGPENG issue of shares and payment of cash benefits to buy their holdings of Thai medicine, after the completion of the acquisition, the benefits of Thai medicine will become a subsidiary of East-medicine.
In order to improve the integration of performance, the company intends to not more than 10 other specific investors to issue shares to raise matching funds 38,000 yuan, the total funds raised matching assets to be purchased does not exceed 100% of the transaction price. Issued shares to buy assets and raise matching funds are the reserve price 36.21 yuan / share.
The issue of shares and payment of cash to acquire a 70% stake in Thai biology and the acquisition of 83.5% stake in Thai medicine are not mutually beneficial premise implementation of any transaction does not affect the implementation of another transaction. The restructuring does not constitute a major asset restructuring.